Journal
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 156, Issue 5, Pages 555-562Publisher
BIO SCIENTIFICA LTD
DOI: 10.1530/EJE-06-0753
Keywords
-
Categories
Funding
- NIA NIH HHS [R01 AG007181, R01 AG007181-13, AG07181, R37 AG007181] Funding Source: Medline
Ask authors/readers for more resources
Objective: The role of osteoprotegerin (OPG) and its receptor activator of nuclear factor kappa B legend (RANKL) in the regulation of bone in humans remain unclear. We examined the sex-specific associations of serum OPG, RANKL, and their ratio with bone mineral density (BMD) in older adults. Design: Participants were 681. community-dwelling adults, ages 45-90 years, who had serum OPG and RANKL measured and bone density scans in 1988-1991, with follow-up scans 5 and/or 10 years later. Methods: Analyses were sex-specific; women using and not using estrogen were evaluated separately. Cross-sectional analyses used multivariable regression models: longitudinal analyses used repeated measures mixed effects models. Results: In cross-sectional analyses, age- and weight-adjusted serum OPG levels were significantly positively associated with BMD at the lumbar spine in men, and Lit the femoral neck, total hip, and lumbar spine in women using estrogen, but not in non-users of estrogen. RANKL concentrations were significantly and inversely associated with BMD in men only, and at the total hip. Neither OPG nor RANKL was significantly associated with bone loss. Results for the RANKL/OPG ratio were the same as those for RANKL alone. Conclusions: These results suggest a modulatory effect of both endogenous and exogenous sex hormones on the biologic interaction of OPG, RANKL, and bone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available